Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN versus INVOKANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN versus INVOKANA.
DAPAGLIFLOZIN vs INVOKANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and lowering blood glucose.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
10 mg orally once daily.
100 mg orally once daily, before the first meal of the day; may increase to 300 mg once daily if tolerated and eGFR is adequate.
None Documented
None Documented
Terminal elimination half-life is approximately 12.9 hours (range 10-16 hours) for dapagliflozin, supporting once-daily dosing. At steady state, effective half-life is ~23 hours due to metabolite.
Clinical Note
moderateDapagliflozin + Gatifloxacin
"Dapagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateDapagliflozin + Rosoxacin
"Dapagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateDapagliflozin + Levofloxacin
"Dapagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateDapagliflozin + Trovafloxacin
"Dapagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is 10.6 hours (range 9.5–12.5 h) in healthy subjects; allows once-daily dosing. Half-life increases to 16 hours in moderate renal impairment and 22 hours in severe renal impairment.
Primarily renal and fecal: ~75% of dose excreted in urine (as unchanged dapagliflozin and glucuronide conjugates), ~21% in feces. Biliary elimination is negligible.
Primarily excreted unchanged in urine (33%) and feces (52%) as parent drug and glucuronide metabolites; renal clearance accounts for 70% of total clearance, with 51% renally excreted as unchanged drug.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor